<DOC>
	<DOCNO>NCT02303730</DOCNO>
	<brief_summary>The purpose study evaluate whether exenatide superior insulin glargine ( 24 week ) reduce liver fat content ( MRS ) patient newly diagnose type 2 diabetes mellitus concomitant non-alcoholic fatty-liver disease ( NAFLD ) .</brief_summary>
	<brief_title>Exenatide Compared With Insulin Glargine Change Liver Fat Content Type 2 Diabetes</brief_title>
	<detailed_description>This randomize , open-label , parallel-group , active control , multi-center clinical trial investigate whether exenatide superior insulin glargine reduce liver fat content patient newly diagnose type 2 diabetes mellitus concomitant NAFLD.Patients type 2 diabetes concomitant NAFLD 18-70 year age , inadequate glycaemic control define 7 % ≤ HbA1c ≤ 9 % BMI≥24kg/ m2 time screen . Patients diet exercise drug treatment naive , use glucagon-like peptide-1 ( GLP-1 ) analogues insulin within 3 month enrolment.Patients screen period 2 week , 24-week open label treatment period . All demographic data variable collect descriptive analysis test use . Qualitative variable use absolute frequency percentage , numeric variable use average , mean , median , standard deviation , maximum , minimum , quartile , etc . Unless specifically state , statistical significance define P＜0.05 whole analysis procedure.For primary endpoint study , superiority test apply quantitative data two group . For secondary exploratory efficacy variable , difference test use analyse repeated measurement data two group . For essential Safety parameter , difference test use analyse difference two groups.The analysis primary secondary endpoint efficacy safety must base Full Analysis Set ( FAS ) . As support evidence , analysis primary endpoint variable must also comply Pre-protocol ( PPS ) Analysis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male female , 18 ≤ age ≤ 70 year old . Newly diagnose type 2 diabetes mellitus ( WHO Diagnostic criterion diabetes mellitus , 1999 ) . Patients NAFLD , MRS measurement liver fat content &gt; 10 % . 7 % ≤ HbA1c ≤ 10 % No heavy drinking history within last 5 year ( alcohol intake : male &lt; 20 g/d , female &lt; 10 g/d ) HBsAg ( ) , hepatitis C virus antibody ( HCVAb ) ( ) BMI ≥ 24 kg/m2 ; Pregnancy , lactation , intended pregnancy , failure take adequate contraceptive measure take ( contraception measure include sterilization , intrauterine device , oral contraceptive , persistent use condom ) . Type 1 diabetes mellitus , gestational diabetes mellitus special type diabetes . Liver renal dysfunction ( ALT aspartate aminotransferase ( AST ) 2.5 time high upper limit normal , total bilirubin 1.5 time high upper limit normal , Cr ≥ 115 μmol/L ) . increase amylase ( blood amylase 2.5 time high upper limit normal ) presence gastrointestinal disease . Use drug may affect liver fat content within one month trial period , glucocorticoid , thyroid hormone , etc . Use GLP1 receptor agonist , dipeptidyl peptidase 4 ( DPP4 ) inhibitor insulin within 3 month enrolment Presence serious dyslipidemia endocrine disease ( hypothyroidism , hypothalamicpituitary dysfunction , etc ) . Fatty liver cause viral hepatitis , drug , alcohol , Wilson disease total parenteral nutrition . Presence liver cancer , infection , biliary tract disease recently increase liver enzyme due medication . Participation strenuous exercise administration drug affect glucose metabolism . History pancreatitis , alcohol abuse , metal disorder history allergy investigational drug . Congestive heart failure define New York Heart Association ( NYHA ) class III IV , unstable angina myocardial infarction recent 6 month . Any situation may affect implementation result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Non-alcoholic Fatty Liver Disease</keyword>
</DOC>